Get the Stockscreener App
0.9272
1.90%
0.0173
Neurosense Therapeutics Ltd stock is traded at $0.9272, with a volume of 65,522.
It is up +1.90% in the last 24 hours and up +15.89% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$0.9099
Open:
$0.92
24h Volume:
65,522
Relative Volume:
0.20
Market Cap:
$27.54M
Revenue:
-
Net Income/Loss:
$-10.21M
P/E Ratio:
-1.587
EPS:
-0.5842
Net Cash Flow:
-
1W Performance:
-4.13%
1M Performance:
+15.89%
6M Performance:
-54.33%
1Y Performance:
-10.85%
1-Day Range:
$0.8801
$0.95
1-Week Range:
$0.8701
$0.99
52-Week Range:
$0.6801
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.9272 | 27.02M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.40 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.24 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
841.53 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
350.93 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.86 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
Aug Retail: Will TILE benefit from seasonality2025 Valuation Update & Daily Growth Stock Tips - baoquankhu1.vn
Short Covering: Can SNVPRE expand into new marketsOil Prices & Verified Momentum Stock Watchlist - baoquankhu1.vn
Breakouts Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buying2025 Winners & Losers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Valuation Update: What is DMACs revenue forecastEarnings Overview Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN
New Alzheimer’s treatment from NeuroSense gets U.S. patent through 2043 - Stock Titan
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease - Finviz
Analyst Calls: Is NeuroSense Therapeutics Ltd gaining market sharePortfolio Value Report & Proven Capital Preservation Methods - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd. a momentum stockFed Meeting & Long Hold Capital Preservation Tips - bollywoodhelpline.com
Portfolio Shifts: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingJuly 2025 Update & Long-Term Capital Growth Ideas - baoquankhu1.vn
Big Picture: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingQuarterly Investment Review & Free High Return Stock Watch Alerts - baoquankhu1.vn
Weekly Trades: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2025 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
Ideas Watch: Will NeuroSense Therapeutics Ltd face regulatory challengesWeekly Trend Report & Technical Pattern Based Signals - baoquankhu1.vn
Weekly Trades: Why is NeuroSense Therapeutics Ltd stock going downInsider Selling & Daily Profit Focused Screening - baoquankhu1.vn
Aug Highlights: Is SNOA likely to announce a buybackIPO Watch & Fast Entry High Yield Tips - baoquankhu1.vn
Earnings Recap: Will NeuroSense Therapeutics Ltd Equity Warrant stock go up in YEARJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
RSI Check: Why NeuroSense Therapeutics Ltd stock appeals to analysts2025 Breakouts & Breakdowns & Daily Profit Focused Stock Screening - Bộ Nội Vụ
Bear Alert: Can NeuroSense Therapeutics Ltd stock beat analyst upgradesJuly 2025 Price Swings & Weekly High Momentum Picks - Bộ Nội Vụ
Risk Hedge: Is NeuroSense Therapeutics Ltd stock a good choice for value investorsJuly 2025 PostEarnings & Verified Swing Trading Watchlists - Bộ Nội Vụ
How NeuroSense Therapeutics Ltd. stock benefits from tech adoptionEarnings Recap Summary & Verified Entry Point Signals - ulpravda.ru
Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analystsProfit Target & Weekly High Return Stock Forecasts - Улправда
Will NeuroSense Therapeutics Ltd. stock remain a Wall Street favorite2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
Technical Analysis: What risks investors should watch in NeuroSense Therapeutics Ltd stockRate Cut & Verified Stock Trade Ideas - Bộ Nội Vụ
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB - Sahm
What risks investors should watch in NeuroSense Therapeutics Ltd. stockForecast Cut & Precise Swing Trade Entry Alerts - ulpravda.ru
Is NeuroSense Therapeutics Ltd. stock resilient to inflationGlobal Markets & Weekly High Momentum Picks - Улправда
Will NeuroSense Therapeutics Ltd. Equity Warrant stock recover faster than peersJuly 2025 WrapUp & Weekly Market Pulse Updates - Улправда
NeuroSense Therapeutics Ltd.Ordinary Shares (NQ: NRSN - FinancialContent
How NeuroSense Therapeutics Ltd. Equity Warrant stock responds to policy changesWeekly Risk Summary & Weekly High Potential Alerts - Улправда
Can NeuroSense Therapeutics Ltd. stock resist sector downturnsWeekly Investment Recap & High Return Stock Watch Alerts - Улправда
Trading Recap: Will NeuroSense Therapeutics Ltd. (H1Z) stock justify high valuation2025 Price Momentum & Fast Gain Stock Tips - Улправда
Can NeuroSense Therapeutics Ltd. stock continue upward trendBreakout Watch & Free AI Powered Buy and Sell Recommendations - Улправда
Is NeuroSense Therapeutics Ltd. Equity Warrant stock a good choice for value investors2025 Support & Resistance & Precise Swing Trade Alerts - Улправда
NeuroSense Therapeutics Ltd. Appoints Prof. Steven E. Arnold to Scientific Advisory Board - MarketScreener
Hedge Fund Bets: How NeuroSense Therapeutics Ltd. Equity Warrant stock performs after earningsJuly 2025 Intraday Action & Weekly Setup with ROI Potential - Улправда
Harvard Alzheimer’s doctor joins biotech developing neurodegenerative treatments - Stock Titan
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash - TipRanks
How NeuroSense Therapeutics Ltd. stock compares to growth peers2026 world cup usa national team semifinals defensive leaders set piece tactics match prediction analysis - ulpravda.ru
NeuroSense Therapeutics (NASDAQ:NRSN) Upgraded by Wall Street Zen to Hold Rating - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study - Sahm
NeuroSense Unveils Favourable Safety Analysis Data Of PrimeC In NST-AD-001 Study For Alzheimer's - Nasdaq
NeuroSense Therapeutics (NASDAQ:NRSN) Receives Buy Rating from D. Boral Capital - Defense World
D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq
NeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial - TipRanks
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile By Investing.com - Investing.com South Africa
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile - Investing.com
Experimental Alzheimer's combo shows no serious side effects in trial - Stock Titan
Rally Mode: Is Capella Minerals Limited (N7D) stock worth buying before Fed actionEarnings Overview Summary & Safe Capital Investment Plans - moha.gov.vn
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.57%
3.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):